Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 3
2(33.3%)
6Total
Phase 2(4)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07339488Phase 2Active Not Recruiting

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

Role: lead

NCT07071103Phase 2Recruiting

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

Role: lead

NCT06076135Phase 2Active Not Recruiting

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors

Role: lead

NCT05189028Phase 3Recruiting

Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer

Role: lead

NCT03744819Recruiting

Biomarkers for Prediction of Tumor Response to Radiotherapy

Role: lead

NCT05188716Completed

Mechanisms and Biomarkers for Tumor Immunogenicity Modulation in Cervical Cancer

Role: lead

NCT02556762Phase 3Active Not Recruiting

Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer

Role: lead

NCT01670409Phase 2Completed

Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer

Role: lead

All 8 trials loaded